In vivo metabolic imaging of Traumatic Brain Injury.

Complex alterations in cerebral energetic metabolism arise after traumatic brain injury (TBI). To date, methods allowing for metabolic evaluation are highly invasive, limiting our understanding of metabolic impairments associated with TBI pathogenesis. We investigated whether 13C MRSI of hyperpolarized (HP) [1-13C] pyruvate, a non-invasive metabolic imaging method, could detect metabolic changes in controlled cortical injury (CCI) mice (n = 57). Our results show that HP [1-13C] lactate-to-pyruvate ratios were increased in the injured cortex at acute (12/24 hours) and sub-acute (7 days) time points after injury, in line with decreased pyruvate dehydrogenase (PDH) activity, suggesting impairment of the oxidative phosphorylation pathway. We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 to deplete brain resident microglia prior to and after CCI, in order to confirm that modulations of HP [1-13C] lactate-to-pyruvate ratios were linked to microglial activation. Despite CCI, the HP [1-13C] lactate-to-pyruvate ratio at the injury cortex of microglia-depleted animals at 7 days post-injury remained unchanged compared to contralateral hemisphere, and PDH activity was not affected. Altogether, our results demonstrate that HP [1-13C] pyruvate has great potential for in vivo non-invasive detection of cerebral metabolism post-TBI, providing a new tool to monitor the effect of therapies targeting microglia/macrophages activation after TBI

METB-14. DOWN-REGULATION OF ACETATE METABOLISM TOWARDS FATTY ACIDS IN IDH1 MUTANT GLIOMA

Abstract Acetate has recently been identified as a major alternative source of nutrients for glioblastoma and brain metastases. After cellular uptake, acetate is converted to acetyl-CoA, a key metabolic intermediate that fuels the TCA cycle and is an essential building block for the biosynthesis of fatty acids. Interestingly, the potential role of acetate in lower-grade glioma harboring the isocitrate dehydrogenase 1 mutation has not yet been elucidated. The goal of this study was therefore to investigate the role of acetate in fatty acid biosynthesis using a well-characterized genetically-engineered cell model that overexpresses either wild-type IDH1 (IDHwt) or mutant IDH1 (IDHmut): an immortalized normal human astrocyte (NHA)-based model. We used 1H and 13C magnetic resonance spectroscopy to quantify the flux of [1,2-13C]-acetate to 13C fatty acids. Our results indicated that the total levels of fatty acids were not significantly different between IDHmut and IDHwt NHA cells. However, the flux of 13C-labeled acetate towards fatty acids was significantly reduced by ~60% in IDHmut NHA cells relative to IDHwt NHA cells. To investigate this disconnect and understand the underlying biological mechanisms, we performed cell biological assays. Surprisingly, this decrease in acetate metabolism was associated with a drop in fatty acid synthase and ATP citrate lyase expressions, two enzymes involved in fatty acid synthesis from acetyl-CoA, in IDHmut NHA cells, whereas expression of acetyl-CoA synthase (AceS1), the cytosolic enzyme converting acetate to acetyl-CoA, was not altered. A significant drop in lipid droplet accumulation was also observed in IDHmut NHA cells as indicated using a spectrophotometric assay. Taken together, this points to alternate sources for fatty acids (e.g. glucose, glutamine, uptake from serum) in IDH1mut cells and suggests that fatty acids are preferentially directed towards cell membrane assembly. It also highlights the unique metabolic reprogramming of mutant IDH1 cells

1 H-13 C independently tuned radiofrequency surface coil applied for in vivo hyperpolarized MRI.

PurposeTo develop a lump-element double-tuned common-mode-differential-mode (CMDM) radiofrequency (RF) surface coil with independent frequency tuning capacity for MRS and MRI applications.MethodsThe presented design has two modes that can operate with different current paths, allowing independent frequency adjustment. The coil prototype was tested on the bench and then examined in phantom and in vivo experiments.ResultsStandard deviations of frequency and impedance fluctuations measured in one resonator, while changing the tuning capacitor of another resonator, were less than 13 kHz and 0.55 Ω. The unloaded S21 was -36 dB and -41 dB, while the unloaded Q factor was 260 and 287, for 13 C and 1 H, respectively. In vivo hyperpolarized 13 C MR spectroscopy data demonstrated the feasibility of using the CMDM coil to measure the dynamics of lactate, alanine, pyruvate and bicarbonate signal in a normal rat head along with acquiring 1 H anatomical reference images.ConclusionIndependent frequency tuning capacity was demonstrated in the presented lump-element double-tuned CMDM coil. This CMDM coil maintained intrinsically decoupled magnetic fields, which provided sufficient isolation between the two resonators. The results from in vivo experiments demonstrated high sensitivity of both the 1 H and 13 C resonators. Magn Reson Med 76:1612-1620, 2016. © 2015 International Society for Magnetic Resonance in Medicine

In vivo metabolic imaging of Traumatic Brain Injury.

Complex alterations in cerebral energetic metabolism arise after traumatic brain injury (TBI). To date, methods allowing for metabolic evaluation are highly invasive, limiting our understanding of metabolic impairments associated with TBI pathogenesis. We investigated whether 13C MRSI of hyperpolarized (HP) [1-13C] pyruvate, a non-invasive metabolic imaging method, could detect metabolic changes in controlled cortical injury (CCI) mice (n = 57). Our results show that HP [1-13C] lactate-to-pyruvate ratios were increased in the injured cortex at acute (12/24 hours) and sub-acute (7 days) time points after injury, in line with decreased pyruvate dehydrogenase (PDH) activity, suggesting impairment of the oxidative phosphorylation pathway. We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 to deplete brain resident microglia prior to and after CCI, in order to confirm that modulations of HP [1-13C] lactate-to-pyruvate ratios were linked to microglial activation. Despite CCI, the HP [1-13C] lactate-to-pyruvate ratio at the injury cortex of microglia-depleted animals at 7 days post-injury remained unchanged compared to contralateral hemisphere, and PDH activity was not affected. Altogether, our results demonstrate that HP [1-13C] pyruvate has great potential for in vivo non-invasive detection of cerebral metabolism post-TBI, providing a new tool to monitor the effect of therapies targeting microglia/macrophages activation after TBI

TMOD-20. EARLY DETECTION OF HDAC INHIBITION IN GLIOBLASTOMA USING ADVANCED HYPERPOLARIZED 13C MRSI

Abstract Today, there is no reliable noninvasive imaging method available to monitor glioblastoma (GBM) response to therapy and predict survival prior to tumor shrinkage. Dissolution Dynamic Nuclear Polarization (DNP) combined with hyperpolarized 13C Magnetic Resonance Spectroscopic Imaging (MRSI) is a novel imaging method that allows probing real-time tumor metabolism. Recent studies using 13C MRSI have shown decreased lactate production from pyruvate in GBM responsive to a dual PI3K/mTOR inhibitor and/or Temozolomide, mediated by lower expression of LDHA or PKM2 enzymes, respectively. SAHA, the histone deacetylase (HDAC) inhibitor, is a novel drug that inhibits cell proliferation by inducing cell cycle arrest followed by apoptosis. The goal of this study was to detect early HDAC inhibition using advanced 13C MRSI. Analysis of dynamic real-time cellular metabolic changes in SAHA-treated U87 live cells in bioreactors demonstrated a significant 37.7% decrease in hyperpolarized [1-13C]-lactate production. SAHA-treated cells also showed a 29.6% decrease of steady-state lactate level in cell extracts. Furthermore, we demonstrated a significant 30.3% decrease in hyperpolarized lactate-to-pyruvate ratio in SAHA-treated U87-bearing mice, which occurred prior to MRI-detectable changes in tumor size that was associated with enhanced animal survival. In order to mechanistically validate our findings, we tested the levels of expression of LDHA, MCT1 and MCT4, the main players in pyruvate-to-lactate interconversion. While expression of LDHA, the enzyme that catalyzes pyruvate-to-lactate conversion was independent of SAHA treatment, expression of both MCT1 and MCT4 transporters, that shuttle pyruvate and lactate in and out of the cell, are increased. We thus propose that increased MCT1/4 led to a decrease in lactate in response to HDAC inhibition and resulted in a reduced pyruvate-to-lactate conversion. Our findings confirm the potential translational value of the hyperpolarized lactate-to-pyruvate ratio as a biomarker for noninvasively assessing the early effects of emerging therapies for patients with GBM

PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.

70-90% of low-grade gliomas and secondary glioblastomas are characterized by mutations in isocitrate dehydrogenase 1 (IDHmut). IDHmut produces the oncometabolite 2-hydroxyglutarate (2HG), which drives tumorigenesis in these tumors. The phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway represents an attractive therapeutic target for IDHmut gliomas, but noninvasive indicators of drug target modulation are lacking. The goal of this study was therefore to identify magnetic resonance spectroscopy (MRS)-detectable metabolic biomarkers associated with IDHmut glioma response to the dual PI3K/(mTOR) inhibitor XL765. 1H-MRS of two cell lines genetically modified to express IDHmut showed that XL765 induced a significant reduction in several intracellular metabolites including 2HG. Importantly, examination of an orthotopic IDHmut tumor model showed that enhanced animal survival following XL765 treatment was associated with a significant in vivo 1H-MRS detectable reduction in 2HG but not with significant inhibition in tumor growth. Further validation is required, but our results indicate that 2HG could serve as a potential noninvasive MRS-detectable metabolic biomarker of IDHmut glioma response to PI3K/mTOR inhibition